tert-butyl 4-(hydroxy(pyridin-4-yl)methyl)piperidine-1-carboxylate | 333986-13-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: tert-butyl 4-(hydroxy(pyridin-4-yl)methyl)piperidine-1-carboxylate
• 英文别名: 1-tert-Butoxycarbonyl-4-[hydroxy(4-pyridyl)methyl]piperidine；1-tert-Butoxycarbonyl-4-[hydroxy(pyridin-4-yl)methyl]piperidine；Tert-butyl 4-[hydroxy(pyridin-4-yl)methyl]piperidine-1-carboxylate
• CAS: 333986-13-3
• 化学式: C₁₆H₂₄N₂O₃
• 分子量: 292.378
• InChiKey: IUEYNOHMWARYBS-UHFFFAOYSA-N

物化性质

• 沸点：
  436.1±20.0 °C(Predicted)
• 密度：
  1.148±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  62.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-(hydroxy(pyridin-4-yl)methyl)piperidine-1-carboxylate 在 咪唑 、 碘 、 三苯基膦 作用下， 以 四氢呋喃 为溶剂， 反应 16.0h， 以50%的产率得到tert-butyl 4-(4-pyridylmethyl)piperidine-1-carboxylate
  参考文献：
  名称：

  α-杂芳基取代的甲醇衍生物脱氧的温和条件

  摘要：

  已经确定了通过PPh 3 / I 2 /咪唑使取代的甲醇衍生物脱氧的温和条件。发现这种无金属的方法在被一个或两个杂芳基取代的仲或叔醇上可以很好地进行，并且可以耐受酸敏感的杂环。此条件适用于被2-吡啶基，4-吡啶基或其他杂环基取代的甲醇衍生物，从而使反应过程中形成的负电荷共振成氮原子。在该条件下，被3-吡啶基或杂环基取代的甲醇衍生物不允许在反应过程中形成的负电荷共振到氮原子上。

  DOI：

  10.1021/acs.joc.1c00067
• 作为产物：
  描述：

  4-溴吡啶 、 1-叔丁氧羰基哌啶-4-甲醛 在 异丙基氯化镁 作用下， 以 四氢呋喃 为溶剂， 生成 tert-butyl 4-(hydroxy(pyridin-4-yl)methyl)piperidine-1-carboxylate
  参考文献：
  名称：

  4-Piperidines and 3-pyrrolidines as dual serotonin and noradrenaline reuptake inhibitors: Design, synthesis and structure–activity relationships

  摘要：

  Single enantiomer [(aryloxy)(pyridinyl) methyl] piperidine and pyrrolidine derivatives 5-9 are inhibitors of monoamine reuptake. Structure-activity relationships established that monoamine reuptake inhibition are functions of amine, pyridine isomer, aryloxy ring substitution and stereochemistry. Consequently, selective NRIs, selective SRIs, dual SNRIs and triple SNDRIs were all identified. Dual SNRIs 51-a and 9c were evaluated in additional pharmacology and pharmacokinetic studies as representative examples from this series. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.03.090

文献信息

• [EN] CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS<br/>[FR] COMPOSES D'AMINE CYCLIQUE UTILISES COMME ANTAGONISTES DE CCR5
  申请人：TAKEDA CHEMICAL INDUSTRIES LTD

  公开号：WO2001025200A1

  公开（公告）日：2001-04-12

  A compound of formula (I) (wherein R1 is a hydrogen atom, a hydrocarbon group which may be substituted, a non-aromatic heterocyclic group which may be substituted, R2 is a hydrocarbon group which may be substituted, a non-aromatic heterocyclic group which may be substituted, or R?1 and R2¿ may combine to each other together with A to form a heterocyclic group which may be substituted; A is N or N?+-R5 •Y-(R5¿ is a hydrocarbon group; Y- is a counter anion); R3 is a cyclic hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; n is 0 or 1; R4 is a hydrogen atom, a hydrocarbon group which may be substituted, a heterocyclic group which may be substituted, an alkoxy group which may be substituted, an aryloxy group which may be substituted, or an amino group which may be substituted, E is a divalent aliphatic hydrocarbon group which may be substituted by group(s) other than oxo; G1 is a bond, CO or SO¿2; G?2 is CO, SO¿2?, NHCO, CONH or OCO; J is methine or a nitrogen atom; and each of Q and R is a bond or a divalent C1-3 aliphatic hydrocarbon which may be substituted; provided that J is methine when G2 is OCO, that one of Q and R is not a bond when the other is a bond and that each of Q and R is not substituted by oxo group(s) when G?1¿ is a bond) or a salt thereof has a potent CCR5 antagonistic activity and can be advantageously used for the treatment or prevention of infectious disease of various HIV in human (e.g. AIDS).

  化合物式为（I）（其中R1是氢原子，可被取代的碳氢基团，可被取代的非芳香杂环基团，R2是可被取代的碳氢基团，可被取代的非芳香杂环基团，或R1和R2可以与A一起结合形成可被取代的杂环基团；A是N或N+ -R5 • Y-（R5是碳氢基团；Y-是反离子）；R3是可被取代的环烃基团或可被取代的杂环基团；n为0或1；R4是氢原子，可被取代的碳氢基团，可被取代的杂环基团，可被取代的烷氧基，可被取代的芳氧基，或可被取代的氨基，E是可被除氧基以外的基取代的二价脂肪烃基团；G1是键，CO或SO2；G2是CO，SO2，NHCO，CONH或OCO；J是甲基或氮原子；Q和R中的每一个都是一个键或一个可被取代的二价C1-3脂肪基团；前提是当G2是OCO时，J是甲基，当另一个是键时，其中一个不是键，当G1是键时，Q和R中的每一个都没有被氧基团取代）或其盐具有强效的CCR5拮抗活性，并可用于人类各种HIV感染疾病（例如艾滋病）的治疗或预防。
• Chemokine receptor binding compounds
  申请人：Zhou Yuanxi

  公开号：US20050277670A1

  公开（公告）日：2005-12-15

  The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR5. These compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).

  本发明涉及化学因子受体结合化合物、制药组合物及其使用。更具体地，本发明涉及化学因子受体活性调节剂，优选为CCR5的调节剂。这些化合物表现出对人类免疫缺陷病毒（HIV）感染靶细胞的保护作用。
• Cyclic amine compounds as CCR5 antagonists
  申请人：——

  公开号：US20030114443A1

  公开（公告）日：2003-06-19

  A compound of formula (I) (wherein R 1 is a hydrogen atom, a hydrocarbon group which may be substituted, a non-aromatic heterocyclic group which may be substituted, R 2 is a hydrocarbon group which may be substituted, a non-aromatic heterocyclic group which may be substituted, or R 1 and R 2 may combine to each other together with A to form a heterocyclic group which may be substituted; A is N or N + —R 5 .Y − (R 5 is a hydrocarbon group; Y − is a counter anion); R 3 is a cyclic hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; n is 0 or 1; R 4 is a hydrogen atom, a hydrocarbon group which may be substituted, a heterocyclic group which may be substituted, an alkoxy group which may be substituted, an aryloxy group which may be substituted, or an amino group which may be substituted, E is a divalent aliphatic hydrocarbon group which may be substituted by group(s) other than oxo; G 1 is a bond, CO or SO 2 ; G 2 is CO, SO 2 , NHCO, CONH or OCO; J is methine or a nitrogen atom; and each of Q and R is a bond or a divalent C 1-3 aliphatic hydrocarbon which may be substituted; provided that J is methine when G 2 is OCO, that one of Q and R is not a bond when the other is a bond and that each of Q and R is not substituted by oxo group(s) when G 1 is a bond) or a salt thereof has a potent CCR5 antagonistic activity and can be advantageously used for the treatment or prevention of infectious disease of various HIV in human (e.g. AIDS).

  化合物的式子 (I) (其中R1是氢原子、可以被取代的碳氢基团、可以被取代的非芳香族杂环基团，R2是可以被取代的碳氢基团、可以被取代的非芳香族杂环基团，或R1和R2可以与A结合形成可以被取代的杂环基团；A是N或N+—R5.Y−(R5是碳氢基团；Y−是反离子)；R3是可以被取代的环烃基团或可以被取代的杂环基团；n为0或1；R4是氢原子、可以被取代的碳氢基团、可以被取代的杂环基团、可以被取代的烷氧基、可以被取代的芳氧基，或可以被取代的氨基团；E是可以被取代的二价脂肪烃基团，该基团可以被除氧基团外的其他基团取代；G1是键、CO或SO2；G2是CO、SO2、NHCO、CONH或OCO；J是甲基或氮原子；Q和R中的每一个都是键或可以被取代的二价C1-3脂肪基团；但是当G2是OCO时，J是甲基；当Q和R中的一个是键时，另一个不是键；当G1是键时，Q和R中的每一个都没有被氧基团取代)或其盐具有强效的CCR5拮抗活性，可以用于治疗或预防人类各种HIV感染性疾病（例如艾滋病）。
• Cyclic Amine Compounds as CCR5 Antagonists
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1886994A1

  公开（公告）日：2008-02-13

  A compound of the formula: (wherein R1 is a hydrogen atom, a hydrocarbon group which may be substituted, a non-aromatic heterocyclic group which may be substituted, R2 is a hydrocarbon group which may be substituted, a non-aromatic heterocyclic group which may be substituted, or R1 and R2 may combine to each other together with A to form a heterocyclic group which may be substituted; A is N or N+-R5 . Y- (R5 is a hydrocarbon group; Y- is a counter anion) ; R3 is a cyclic hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; n is 0 or 1; R4 is a hydrogen atom, a hydrocarbon group which may be substituted, a heterocyclic group which may be substituted, an alkoxy group which may be substituted, an aryloxy group which may be substituted, or an amino group which may be substituted, E is a divalent aliphatic hydrocarbon group which may be substituted by group (s) other than oxo;G1 is a bond, CO or SO2 ; G2 is CO,S02, NHCO, CONH or OCO ; J is methine or a nitrogen atom; and each of Q and R is a bond or a divalent C1-3 aliphatic hydrocarbon which may be substituted; provided that J is methine when G2 is OCO, that one of Q and R is not a bond when the other is a bond and that each of Q and R is not substituted by oxo group (s) whenGo ils a bond) or a salt thereof has a potent CCR5 antagonistic activity and can be advantageously used for the treatment or prevention of infectious disease of various HIV in humans (e.g. AIDS).

  式中的化合物： (其中 R1 是氢原子、可被取代的烃基、可被取代的非芳香杂环基团，R2 是可被取代的烃基、可被取代的非芳香杂环基团，或 R1 和 R2 可与 A 相互结合形成可被取代的杂环基团；A 是 N 或 N+-R5 .Y-（R5 是烃基；Y- 是反阴离子）；R3 是可被取代的环烃基或可被取代的杂环基；n 是 0 或 1；R4 是氢原子、可被取代的烃基、可被取代的杂环基、可被取代的烷氧基、可被取代的芳氧基或可被取代的氨基；E 是可被除氧代以外的基团（s）取代的二价脂肪族烃基；G1 是键、CO 或 SO2；G2 是 CO、S02、NHCO、CONH 或 OCO；J 是甲烷或氮原子；Q 和 R 各自是键或可被取代的二价 C1-3 脂肪族烃；条件是：当 G2 为 OCO 时，J 为甲烷；当另一个为键时，Q 和 R 中的一个不是键；当 Go ils 为键时，Q 和 R 中的每一个没有被氧化基团（s）取代）或其盐具有强效的 CCR5 拮抗活性，可有利地用于治疗或预防人类各种 HIV 感染性疾病（如艾滋病）。例如艾滋病）。
• CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1220842A1

  公开（公告）日：2002-07-10